Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Renamed Coave Therapeutics Raises $39m To Fund Its Next-Gen Gene Therapies

Conjugation Tech Could Improve Gene Delivery

Executive Summary

The company aims to overcome drawbacks of existing gene therapy platforms, starting in ocular and CNS diseases.

You may also be interested in...



Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy

Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.

GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight

French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.

Lessons Learnt From Aduhelm, Eisai Is Preaching Patience On Alzheimer’s Drug Leqembi

Eisai has spent 25 years looking for a breakthrough in Alzheimer’s and warns that healthcare systems need to undergo a major shift to accommodate its breakthrough drug.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel